FDA Clears Expanded Use of MagVenture TMS Therapy for Adolescents and Young Adults
The U.S. Food and Drug Administration (FDA) has granted clearance for the MagVenture TMS Therapy® system to be used as an adjunctive treatment for Major Depressive Disorder (MDD) in adolescents and young adults aged 15 to 21 who have not…
Defining Treatment-Resistant Bipolar Depression: New Recommendations from the ISBD Task Force
Bipolar disorder is a complex and often debilitating illness that affects 1–2% of the global population. Among its challenges, bipolar depression stands out as the leading cause of disability, poor quality of life, and increased suicide risk. While several medications…
25 Years Later: How the 2000 Nobel Prize Transformed Neuroscience and Medicine
Celebrating a Quarter Century of Scientific Breakthroughs In 2025, we mark the 25th anniversary of one of the most influential Nobel Prizes in neuroscience and medicine. Awarded in 2000, the Nobel Prize in Physiology or Medicine recognized three pioneering scientists—Arvid…
AI in Mind: Can Digital Therapeutics Reshape Mental Healthcare’s Future?
Have you ever battled anxiety or depression and wished that help could be instantly at hand, available any hour in any place? If you have followed recent advances in AI and wondered whether technology can make that possible, you are…
When ECT Doesn’t Work: Next Steps for Treatment-Resistant Depression
Electroconvulsive therapy (ECT) remains one of the most effective interventions for treatment-resistant depression (TRD), with response rates often exceeding 70%. For many patients who have not found relief through psychotherapy or multiple medication trials, ECT can offer life-changing improvement. However,…
From Brexanolone to Psychedelics: The New Frontier in Pharmacologic Psychiatry
After decades of modest advances in psychopharmacology, psychiatry is finally entering a new era—one marked not by incremental adjustments to serotonin pathways, but by bold forays into previously uncharted neurobiological terrain. Novel agents like brexanolone, the first FDA-approved treatment specifically…
The Hidden Delay in ECT for Catatonia Patients
Catatonia is a severe neuropsychiatric syndrome that can leave patients trapped in states of profound motor immobility, mutism, or agitation. It’s a psychiatric emergency—yet far too often, patients with catatonia are caught in therapeutic limbo, receiving escalating doses of benzodiazepines…
The Assessment Framework Behind Treatment-Resistant Depression Specialized Consultation Clinics
In the second installment of their landmark series, the National Network of Depression Centers (NNDC) Task Group deepens the conversation on developing effective care for treatment-resistant depression (TRD) with Part II: Assessment, published in the Journal of Clinical Psychiatry. Following…
Calming and Grounding Techniques
Written By: Amy K. Garcia, PhD, NCSP, LP and Daniela Sosa-Castillo, LMSW Stress According to the World Health Organization (WHO), stress is defined as “a state of worry or mental tension caused by a difficult situation” (WHO, 2023). Humans all…
A Roadmap for Treatment-Resistant Depression Programs
As rates of depression continue to climb worldwide, a new consensus paper offers much-needed guidance for health centers seeking to launch specialized consultation programs for treatment-resistant depression (TRD). Published by a task group from the National Network of Depression Centers…